NCT00646386View on ClinicalTrials.gov

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

April 30, 2004

Conditions
ArthritisPsoriatic
Interventions
DRUG

adalimumab

40 mg eow Week 0 - Week 24

DRUG

placebo for adalimumab

40 mg eow Week 0 - Week 24

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00646386 - Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter